Get the Stockscreener App
31.46
6.09%
-2.04
After Hours:
31.50
0.04
+0.13%
Viking Therapeutics Inc stock is traded at $31.46, with a volume of 9.33M.
It is down -6.09% in the last 24 hours and down -26.03% over the past month.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
See More
Previous Close:
$33.50
Open:
$31.02
24h Volume:
9.33M
Relative Volume:
2.13
Market Cap:
$3.51B
Revenue:
-
Net Income/Loss:
$-99.15M
P/E Ratio:
-33.83
EPS:
-0.93
Net Cash Flow:
$-74.25M
1W Performance:
-6.62%
1M Performance:
-26.03%
6M Performance:
-41.01%
1Y Performance:
+27.83%
1-Day Range:
$29.90
$33.40
1-Week Range:
$29.90
$34.78
52-Week Range:
$23.80
$99.41
Viking Therapeutics Inc Stock (VKTX) Company Profile
Name
Viking Therapeutics Inc
Sector
Industry
Phone
858-704-4660
Address
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
31.46 | 3.51B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Nov-22-24 | Initiated | B. Riley Securities | Buy |
| Nov-04-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-24 | Initiated | JP Morgan | Overweight |
| Jun-27-24 | Initiated | Morgan Stanley | Overweight |
| May-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-26-24 | Reiterated | Oppenheimer | Outperform |
| Mar-07-24 | Initiated | Jefferies | Buy |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| May-31-23 | Resumed | ROTH MKM | Buy |
| Mar-28-23 | Reiterated | Maxim Group | Buy |
| Mar-17-23 | Initiated | Stifel | Buy |
| Jul-29-21 | Resumed | BTIG Research | Buy |
| May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-05-20 | Initiated | BMO Capital Markets | Outperform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| May-01-20 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-25-19 | Initiated | Stifel | Buy |
| Mar-29-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-14-19 | Reiterated | Maxim Group | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Nov-19-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-18-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-18-18 | Reiterated | Maxim Group | Buy |
| Sep-18-18 | Reiterated | Raymond James | Outperform |
| Jul-20-18 | Initiated | SunTrust | Buy |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-01-18 | Reiterated | Laidlaw | Buy |
| May-31-18 | Reiterated | Maxim Group | Buy |
| Mar-26-18 | Resumed | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | Maxim Group | Buy |
| Nov-21-17 | Initiated | ROTH Capital | Buy |
View All
Viking Therapeutics Inc Stock (VKTX) Latest News
Viking Therapeutics Reports Strong Trials and Financial Health - TipRanks
Viking Therapeutics Plunged 6% On Its Earnings Report. Here's Why. - Yahoo! Voices
Viking Therapeutics Reports Q4 2024 Financial Results, Advances VK2735 Trials - Yahoo Finance
Has the Bubble Burst for Viking Therapeutics Stock? - MSN
VKTX's Q4 Loss Wider Than Expected, Sales Nil, Stock Down 10% - Yahoo Finance
Has the Bubble Burst for Viking Therapeutics Stock? - The Motley Fool
Viking Therapeutics Inc (VKTX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising ... - Yahoo Finance
Viking Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Viking Therapeutics Reports Positive 2024 Financials and Clinical Progress - TipRanks
Viking Therapeutics targets Phase 3 trials for VK2735 in Q2 2025 amid strong clinical progress - MSN
Viking Therapeutics : February 2025 Corporate Presentation - Marketscreener.com
Viking Therapeutics Shares Drop After Q4 EPS Miss Estimates - Benzinga
Viking stock slides 8% following Q4 report, pipeline update - Seeking Alpha
Viking Therapeutics, Inc. (VKTX): One of January’s Biggest Losers - Insider Monkey
Viking Therapeutics reports Q4 EPS (32c), consensus (27c) - TipRanks
Viking's Obesity Drug Achieves 14.7% Weight Loss, Phase 3 Launch Set for Q2 - StockTitan
Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update - PR Newswire
BlackRock, Inc. Expands Stake in Viking Therapeutics Inc - GuruFocus.com
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It? - Yahoo Finance
Prediction: This Pharma Stock Will Be the Best Performer in 2025 - 24/7 Wall St.
Why Does Jim Cramer Prefer Eli Lilly (LLY) Over Viking Therapeutics? - MSN
Viking Therapeutics: Why The Oral VK2735 Phase 2 Readout Could Send The Stock Soaring - Seeking Alpha
Can Viking Touch The $100 Mark? - RTTNews
Viking Therapeutics, Inc. (NASDAQ:VKTX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Purchased by Janney Montgomery Scott LLC - MarketBeat
Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Bought by U.S. Capital Wealth Advisors LLC - MarketBeat
Brokerages Set Viking Therapeutics, Inc. (NASDAQ:VKTX) PT at $106.75 - MarketBeat
Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Bought by Institute for Wealth Management LLC. - MarketBeat
Viking Therapeutics (VKTX) to Release Quarterly Earnings on Wednesday - MarketBeat
Viking Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy? - MSN
This Weight Loss Stock Could Soar Over 220%, According to Wall Street. Time to Buy? - sharewise
Jim Cramer’s Take on Viking Therapeutics (VKTX): “Sell Viking Therapeutics and Roll it into Viking Holdings” - Insider Monkey
SG Americas Securities LLC Boosts Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
Exchange Traded Concepts LLC Sells 34,994 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
Jim Cramer’s Thoughts on These 7 Stocks - Insider Monkey
Jim Cramer’s Lightning Rounds: 9 Stocks in Focus - Insider Monkey
Jim Cramer Says ‘I Want You To Sell Viking Therapeutics, Inc. (VKTX) And Roll It Into Viking Holdings’ - Insider Monkey
Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Lewis Asset Management LLC Purchases 10,880 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2024 on February 5, 2025 - Marketscreener.com
Jim Cramer: This Industrial Stock Is 'Absolutely Terrific', First Solar Is 'Very Inexpensive' - Benzinga
(VKTX) Trading Advice - Stock Traders Daily
(VKTX)Analyzing Viking Therapeutics's Short Interest - Benzinga
Institutional investors control 73% of Viking Therapeutics, Inc. (NASDAQ:VKTX) and were rewarded last week after stock increased 5.7% - Simply Wall St
Viking Therapeutics Reveals Encouraging Data From Genetic Disorder Drug Study, Analyst Says Focus On Orphan Disease Broadens Viking's Potential Revenue Streams - MSN
Viking Therapeutics Inc Stock (VKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):